Health Tech Daily Brief - October 15, 2026

Did AI Tools Launch Just Shift Teladoc's (TDOC) Investment Narrative?

The President Directly Oversees the IT Department: An AI Trial of an Innovative Pharmaceutical Company

1 Million Patient Encounters Demonstrate the Shift Toward Ambient Clinical Intelligence and Voice AI for EHRs

When telehealth-only clinics… bulk bill?

HealthTap Introduces Virtual Primary Care Program for DME Suppliers

Hospital-at-Home Monitoring Platforms Market to Reach USD 1.65

eSIM Technology in Medical IoT: How Embedded SIMs Simplify Cellular Device Connectivity

Actigraphy Device Market To 2035: Demand Rises on Sleep Disorder Burden - News and Statistics

Signos Review 2026: FDA-Cleared App, Real Prices, a "30-Day Guarantee" That Isn't a Refund - Is It Right for You?

Hospitals face the cyber resilience challenge: Moving from vulnerability counts to real risk

Epic Systems facility head discusses new Other Worlds campus

Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building

Ultragenyx Pharmaceutical sold two priority review vouchers, each from an FDA approval of a gene therapy. Both therapies came from business deals and proceeds from the voucher sales put Ultragenyx in a better financial position to pursue yet another deal for a rare disease asset. The post Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building appeared first on M…

The FDA Clarified Its Rules for Medical AI. This Stock Could Be on the Right Side of Them

Best Medicare Advantage Plans In Wisconsin 2027

CMS ends Obamacare subsidies for 189,000 with duplicate coverage or listed as deceased

{Funding Alert} Confido Health Raises $12.5 Mn With Backing From Z47, Together Fund and Blume Ventures

Emerging KC startup Treso raises $3.75M to simplify complex healthcare transactions

Tech acquisitions hit 14 as IPOs stall at 1 in Q3

Software as Medicine: Global Trial Map Reveals Where Digital Therapeutics Are Headed

Arkansas sues OpenAI, claiming company misled consumers about ChatGPT safety

Biggest wellness trends of the year, from rucking to zone 2

Character.ai faces 40 attorneys general over who can buy its users' chats